



Myson Century, Inc.

股票代號5314

**The Second Time
Roadshow Presentation
of 2024**

Disclaimer

- Myson's statements of its current expectations are forward-looking statements subject to significant risks and uncertainties and actual results may differ materially from those contained in the forward-looking statements. ◦
- Except as required by law, we undertake no obligation to update forward-looking statement, whether as a result of new information, future events, or otherwise.

Outline

**1. Information Related to
Reinvestment Business**

**2. Analysis of
Operating Status**

3. Future Outlook

4. Conclusion


History

- **The company was established on July 29, 1991. The main business items of the company and its subsidiary (ZAVIO INC.) are research, development, manufacturing and sales of integrated circuit systems and safety monitoring products, as well as technical consulting services And import and export trade business.**
- **Sunyard Construction Co.,LTD. acquired 17% of the company's equity and management rights in 2021, and becomes the parent company of the group.**
- **Newly reinvested catering income in the third quarter of 2023.**

•Due to the aging population trend in Taiwan, in order to take care of the health of all people, the company entered the biotechnology and health platform and established the biotechnology department in November 2012.Start reparing to produce and sell health food.


在這裡輸入內容。

•In January 2013, Hanyu, a subsidiary of the company, began to actively sell clothing and other department stores through live streaming on the Internet platform through technology licensing .



.Our company was originally a well-known IC designer. In order to continue the tradition of technology factories, we established an intelligent machine department in June 2013. We first introduced the development of drones and launched drone IC module chips and range computer control chip modules. The department has strong independent IC development capabilities related to UAV manufacturing and AI data application, especially the development of heavy-duty UAVs. The goal is to enter the field of military, commercial and rescue heavy-duty UAVs.

1.Information Related to Reinvestment Business





2. Analysis of Operating Status

Annual Income Statement Comparison

In Thousand NT\$

	2024/Q3	2023/Q3	YOY (%)
Net Sales	360,227	11,978	2,907.41
Operating Profit	198,347	2,244	8,738.99
Operating Income	141,624	(17,811)	895.15
Non-Operating Income (Expense)	(966)	37,956	(102.55)
Income (Loss) before Income Tax	140,658	20,145	598.23
Net Income(Loss) after Tax	140,658	20,145	598.23
EPS(NT\$)	9.56	1.37	597.81




3.Future Outlook


- The company's management rights changed significantly in July 2021. Therefore, according to the restriction of Article 12-17 of the business rules of the Taipei Exchange, there must be no major changes in business items in the following 8 business quarters. Therefore, the company has to wait until the second half of 2023 to make appropriate adjustments to the current main business activities, and newly reinvested catering income in the third quarter of 2023.



4. Conclusion



The company's operating rights changed significantly in July 2021. Therefore, in accordance with the restrictions of Article 12-17 of the business rules of the counter shopping center, no major changes in business items are allowed in the eight business quarters. Starting from June 30, 2023 The company has lifted the restrictions of this regulation and has begun to prepare and adjust its business projects. In the third quarter of 2023, the company increased its reinvested catering income.



In order to expand the sales channel of Chaohe Biomedical's health food, the company invested in Yunkang Century to directly expand Chaohe Biomedical 's health food sales in addition to online e-commerce through its direct sales communication channel .

In the future, Yunkang Century will continue to expand direct sales points across the country. If this happens , the revenue of Chaohe Biomedical Health Food is expected to increase step by step.

Established sales hotlines such as 0800-367-888 , 0800-619-888 , 0800-678-199 , 0800-700-111 and 0800-863-898 , and purchased star-endorsed product advertisements on TV to market health food in an all-round way.

Thank You



Q&A